Credit Suisse Sticks to Their Buy Rating for Gilead Sciences

By Carrie Williams

Credit Suisse analyst Alethia Young maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) yesterday and set a price target of $82. The company’s shares opened today at $73.20.

According to TipRanks.com, Young is a 2-star analyst with an average return of 0.4% and a 42.7% success rate. Young covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Ionis Pharmaceuticals Inc, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Gilead Sciences is Moderate Buy and the average price target is $88.27, representing a 20.6% upside.

In a report issued on November 30, Maxim Group also upgraded the stock to Buy with a $94 price target.

Gilead Sciences’ market cap is currently $95.79B and has a P/E ratio of 8.35. The company has a book value ratio of 3.8555.

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Gregg Alton, the EVP Comm&Acs ALA, Corp&Med Aff of GILD sold 15,000 shares for a total of $1,119,414.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company’s products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.